MOLECULAR PATHOLOGY, FDA APPROVED

Cytocheck partners with one of the most trusted names in diagnostics, Roche, providing many STI testing options to our referring providers.  The Roche cobas® High Risk HPV test was the first on the market to provide DNA-Based, High Risk HPV results with genotyping on a single run.  This test individually identifies HPV16 and HPV18, along with providing a pooled identification of the other most common genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).  By providing HPV16 & HPV 18 on every result, we equip our providers to more accurately assess individual patient risk based on their HPV status.  Additionally, in offering a test with ß-globin internal cellular control, we help prevent false negative results.  Given the latest consensus guidelines recommending an increased interval between pap smear collection, it is imperative that you can trust a negative result.  Otherwise, false negatives, which are possible on competitor platforms, can lead to bad patient outcomes by the time she is screened again in 3-5 years.

Cytocheck also partners with Roche Diagnostics for CT/NG testing.  In offering these higher volume tests on the same instruments as the High-Risk HPV, we boast a redundant system of instruments to ensure consistent turn-around-times, even during software updates and equipment maintenance.  The Dual-Target approach of cobas® CT/NG of both the genomic and cryptic plasmid DNA of C. trachomatis, ensures inclusion of nvCT strains for a highly sensitive test.  In addition, the use of two sets of primers targeting the highly conserved direct repeat region (DR9) and a conserved sequence variant amplify and detect both wild type and variant versions of N. gonorrhoeae.  In essence, this assay delivers fast results that are highly sensitive and highly specific, ensuring you are equipped to properly manage your patients.

In addition to CT/NG from Roche, we also offer TV/MG (Trichomonas vaginalis/Mycoplasma genitalium) on the same instruments.  Given the latest data from CDC, Mycoplasma genitalium is responsible for 20-35% of non-chlamydial Non-gonococcal urethritis cases in the U.S.  In recognizing this trend, we have made this available through several different collection types.

In addition to these tests offered through Roche Diagnostics, we also have access to a robust menu of Gyn PCR tests.